Literature DB >> 24427351

Expression of metabolism-related proteins in triple-negative breast cancer.

Min-Ju Kim1, Do-Hee Kim1, Woo-Hee Jung1, Ja-Seung Koo1.   

Abstract

To investigate the dominant metabolic type of triple-negative breast cancer (TNBC) and evaluate its clinical implication through analysis of protein expression related to glycolysis, glutaminolysis, and mitochondrial oxidative phosphorylation. Tissue samples from 129 patients with TNBC who underwent mastectomy due to invasive breast cancer from 2000 to 2005 were prepared for tissue microarray. By immunohistochemical staining of the tissue microarrays, the markers of glycolysis-related proteins (Glut-1, CAIX, MCT4), glutaminolysis-related proteins (GLS1, GDH, ASCT2), and mitochondrial enzymes (ATP synthase, SDHA and SDHB) were analyzed. Based on the results, the metabolic phenotypes were defined based on positivity for more than two of three markers for each phenotype as follows: glycolysis type (Glut-1, CAIX and MCT4), glutaminolysis type (GLS1, GDH and ASCT2) and mitochondrial type (ATP synthase, SDHA and SDHB). The percentages of samples with metabolic phenotypes of tumor and stroma of TNBC were as follows: for tumor, mitochondrial type (85.3%)>glutaminolysis type (67.4%)>glycolysis type (63.0%); and for stroma, glutaminolysis type (37.2%)>glycolysis type (16.3%)>mitochondrial type (14.0%). The most common metabolic phenotype of TNBC was glycolysis type for basal-like type and non-glycolysis type for non-basal-like type (p=0.047). The correlation between glutaminolysis and mitochondrial type was statistically significant in both tumor and stroma (p<0.001). In conclusion, tumor cells of TNBC express glycolysis and mitochondrial metabolism-related proteins. Glycolysis type is the most common phenotype of basal-like type, and reversely, non-glycolysis type is the most common phenotype of non basal-like type.

Entities:  

Keywords:  Breast; glutaminolysis; glycolysis; mitochondria; triple-negative breast cancer

Mesh:

Year:  2013        PMID: 24427351      PMCID: PMC3885485     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  28 in total

Review 1.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

2.  Triple-negative breast cancer: clinical features and patterns of recurrence.

Authors:  Rebecca Dent; Maureen Trudeau; Kathleen I Pritchard; Wedad M Hanna; Harriet K Kahn; Carol A Sawka; Lavina A Lickley; Ellen Rawlinson; Ping Sun; Steven A Narod
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

Review 3.  Mitochondrial tumour suppressors: a genetic and biochemical update.

Authors:  Eyal Gottlieb; Ian P M Tomlinson
Journal:  Nat Rev Cancer       Date:  2005-11       Impact factor: 60.716

Review 4.  Glutamine addiction: a new therapeutic target in cancer.

Authors:  David R Wise; Craig B Thompson
Journal:  Trends Biochem Sci       Date:  2010-08       Impact factor: 13.807

5.  Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition.

Authors:  Terence K Lee; Ronnie T P Poon; Anthony P Yuen; Ming Tat Ling; Wei Kei Kwok; Xiang Hong Wang; Yong Chuan Wong; Xin Yuan Guan; Kwan Man; King Lok Chau; Sheung Tat Fan
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

6.  The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma.

Authors:  Stephanos Pavlides; Diana Whitaker-Menezes; Remedios Castello-Cros; Neal Flomenberg; Agnieszka K Witkiewicz; Philippe G Frank; Mathew C Casimiro; Chenguang Wang; Paolo Fortina; Sankar Addya; Richard G Pestell; Ubaldo E Martinez-Outschoorn; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2009-12-05       Impact factor: 4.534

Review 7.  Triple-negative/basal-like breast cancer: review.

Authors:  Emad A Rakha; Ian O Ellis
Journal:  Pathology       Date:  2009-01       Impact factor: 5.306

Review 8.  American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

Authors:  M Elizabeth H Hammond; Daniel F Hayes; Mitch Dowsett; D Craig Allred; Karen L Hagerty; Sunil Badve; Patrick L Fitzgibbons; Glenn Francis; Neil S Goldstein; Malcolm Hayes; David G Hicks; Susan Lester; Richard Love; Pamela B Mangu; Lisa McShane; Keith Miller; C Kent Osborne; Soonmyung Paik; Jane Perlmutter; Anthony Rhodes; Hironobu Sasano; Jared N Schwartz; Fred C G Sweep; Sheila Taube; Emina Emilia Torlakovic; Paul Valenstein; Giuseppe Viale; Daniel Visscher; Thomas Wheeler; R Bruce Williams; James L Wittliff; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2010-04-19       Impact factor: 44.544

9.  The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy.

Authors:  E Y Tan; M Yan; L Campo; C Han; E Takano; H Turley; I Candiloro; F Pezzella; K C Gatter; E K A Millar; S A O'Toole; C M McNeil; P Crea; D Segara; R L Sutherland; A L Harris; S B Fox
Journal:  Br J Cancer       Date:  2009-01-27       Impact factor: 7.640

Review 10.  Triple negative tumours: a critical review.

Authors:  J S Reis-Filho; A N J Tutt
Journal:  Histopathology       Date:  2008-01       Impact factor: 5.087

View more
  8 in total

1.  Blockage of glutaminolysis enhances the sensitivity of ovarian cancer cells to PI3K/mTOR inhibition involvement of STAT3 signaling.

Authors:  Lili Guo; Bo Zhou; Zhengqing Liu; Ying Xu; Hao Lu; Meng Xia; Ensong Guo; Wanying Shan; Gang Chen; Changyu Wang
Journal:  Tumour Biol       Date:  2016-02-19

Review 2.  Tumor mechanics and metabolic dysfunction.

Authors:  Jason C Tung; J Matthew Barnes; Shraddha R Desai; Christopher Sistrunk; Matthew W Conklin; Pepper Schedin; Kevin W Eliceiri; Patricia J Keely; Victoria L Seewaldt; Valerie M Weaver
Journal:  Free Radic Biol Med       Date:  2014-12-19       Impact factor: 7.376

3.  Prediction of Recurrence and Survival for Triple-Negative Breast Cancer (TNBC) by a Protein Signature in Tissue Samples.

Authors:  Mario Campone; Isabelle Valo; Pascal Jézéquel; Marie Moreau; Alice Boissard; Loic Campion; Delphine Loussouarn; Véronique Verriele; Olivier Coqueret; Catherine Guette
Journal:  Mol Cell Proteomics       Date:  2015-07-24       Impact factor: 7.381

4.  Association of cancer metabolism-related proteins with oral carcinogenesis - indications for chemoprevention and metabolic sensitizing of oral squamous cell carcinoma?

Authors:  Martin Grimm; Marcel Cetindis; Max Lehmann; Thorsten Biegner; Adelheid Munz; Peter Teriete; Wiebke Kraut; Siegmar Reinert
Journal:  J Transl Med       Date:  2014-07-21       Impact factor: 5.531

Review 5.  Lactate Metabolism and Immune Modulation in Breast Cancer: A Focused Review on Triple Negative Breast Tumors.

Authors:  Adviti Naik; Julie Decock
Journal:  Front Oncol       Date:  2020-11-26       Impact factor: 6.244

6.  Reduced Expression of Annexin A6 Induces Metabolic Reprogramming That Favors Rapid Fatty Acid Oxidation in Triple-Negative Breast Cancer Cells.

Authors:  Stephen D Williams; Amos M Sakwe
Journal:  Cancers (Basel)       Date:  2022-02-22       Impact factor: 6.575

7.  High expression of monocarboxylate transporter 4 predicts poor prognosis in patients with lung adenocarcinoma.

Authors:  Yushu Ruan; Fanjun Zeng; Zhiqiang Cheng; Xianda Zhao; Pin Fu; Honglei Chen
Journal:  Oncol Lett       Date:  2017-09-15       Impact factor: 2.967

8.  Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities.

Authors:  Nathan J Lanning; Joshua P Castle; Simar J Singh; Andre N Leon; Elizabeth A Tovar; Amandeep Sanghera; Jeffrey P MacKeigan; Fabian V Filipp; Carrie R Graveel
Journal:  Cancer Metab       Date:  2017-08-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.